Janssen Pharmaceutica Nv

Wing S Cheung

Mark R Player

Raymond Joseph Patch

Carl R Illig

William H Parsons

Sanath K Meegalla

Jinsheng Chen

Daniel J Parks

Hui Huang

Scott L Dax

Mark James Wall

Mark Andrew Youngman

Jian Liu

Sharmila Patel

Yu-Kai Lee

Guozhang Xu

Gilles C Bignan

Micheal D Gaul

Kenneth Jerome Wilson

Kenneth M Wells

Bao-Ping Zhao

Michele C Jetter

Raul R Calvo

Wenxi Pan

Xun Li

Davoud Asgari

Michael Richard Brandt

Derek A Beauchamp

Michael R Brandt

Mark A Youngman

Raul L Calvo

Michael Brandt

Disclosed are compounds, compositions and methods for treating Type II diabetes. Such compounds are represented by Formula (I) as follows: wherein R, R, L, and Q are defined herein.

PDE 10a inhibitors for the treatment of type II diabetes

The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

Substituted thiazolidinedione indazoles, indoles and benzotriazoles as estrogen-related receptor-&#x3b1; modulators

The invention is directed to compounds of Formula (I): to pharmaceutical compositions containing such compounds and to methods of treatment using them.

Benzimidazole modulators of VR1

Benzimidazole TRPV1 inhibitors

The invention is directed to compounds of Formulae I and II: wherein R, R, R, R, R, Y, Y, Y, Yand X are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.

Quinolinone derivatives as inhibitors of c-fms kinase

Growing community of inventors

Plainsboro, NJ, United States of America

Wing S Cheung